{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:51:50Z","timestamp":1791327110081,"version":"4.3.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77467-3","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:34:05Z","timestamp":1788539645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cadonilimab plus lenvatinib in advanced endometrial cancer: the multicenter single-arm phase II CLEAR-EC trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4470-2696","authenticated-orcid":false,"given":"Lin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7391-0270","authenticated-orcid":false,"given":"Haixi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoxian","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xielan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0127-2951","authenticated-orcid":false,"given":"Chunyan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"77467_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263, https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"77467_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia, C. et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin. Med. J. 135, 584\u2013590, https:\/\/doi.org\/10.1097\/CM9.0000000000002108 (2022).","journal-title":"Chin. Med. J."},{"key":"77467_CR3","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41416-021-01279-z","volume":"124","author":"ME Barclay","year":"2021","unstructured":"Barclay, M. E., Abel, G. A., Greenberg, D. C., Rous, B. & Lyratzopoulos, G. Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact. Br. J. Cancer 124, 1320\u20131329, https:\/\/doi.org\/10.1038\/s41416-021-01279-z (2021).","journal-title":"Br. J. Cancer"},{"key":"77467_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348, https:\/\/doi.org\/10.3322\/caac.21763 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"77467_CR5","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","volume":"388","author":"RN Eskander","year":"2023","unstructured":"Eskander, R. N. et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. New Engl. J. Med. 388, 2159\u20132170, https:\/\/doi.org\/10.1056\/NEJMoa2302312 (2023).","journal-title":"New Engl. J. Med."},{"key":"77467_CR6","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza, M. R. et al. Dostarlimab for primary advanced or recurrent endometrial cancer. New Engl. J. Med. 388, 2145\u20132158, https:\/\/doi.org\/10.1056\/NEJMoa2216334 (2023).","journal-title":"New Engl. J. Med."},{"key":"77467_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker, V. et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. New Engl. J. Med. 386, 437\u2013448, https:\/\/doi.org\/10.1056\/NEJMoa2108330 (2022).","journal-title":"New Engl. J. Med."},{"key":"77467_CR8","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1158\/1078-0432.CCR-19-3467","volume":"26","author":"AR Parikh","year":"2020","unstructured":"Parikh, A. R. et al. Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. Clin. Cancer Res. 26, 1877\u20131885, https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3467 (2020).","journal-title":"Clin. Cancer Res."},{"key":"77467_CR9","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1093\/clinchem\/hvaa223","volume":"66","author":"SS Lueong","year":"2020","unstructured":"Lueong, S. S. et al. Serial circulating tumor DNA mutational status in patients with KRAS-mutant metastatic colorectal cancer from the phase 3 AIO KRK0207 trial. Clin. Chem. 66, 1510\u20131520, https:\/\/doi.org\/10.1093\/clinchem\/hvaa223 (2020).","journal-title":"Clin. Chem."},{"key":"77467_CR10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1200\/JCO.22.01021","volume":"41","author":"V Makker","year":"2023","unstructured":"Makker, V. et al. A phase Ib\/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (Study 111\/KEYNOTE-146): long-term efficacy and safety update. J. Clin. Oncol. 41, 974\u2013979, https:\/\/doi.org\/10.1200\/JCO.22.01021 (2023).","journal-title":"J. Clin. Oncol."},{"key":"77467_CR11","doi-asserted-by":"publisher","first-page":"9559","DOI":"10.2147\/DDDT.S548735","volume":"19","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. Real-world efficacy of cadonilimab plus chemotherapy as second-line therapy in immunotherapy-pretreated advanced HER2 negative gastric or gastroesophageal junction cancer. Drug Des. Dev. Ther. 19, 9559\u20139569, https:\/\/doi.org\/10.2147\/DDDT.S548735 (2025).","journal-title":"Drug Des. Dev. Ther."},{"key":"77467_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e17502","volume":"43","author":"X Li","year":"2025","unstructured":"Li, X. et al. Efficacy and safety of cadonilimab in recurrent\/metastatic solid tumors including ICI-treated tumors in clinical practice: cohorts of head and neck squamous cell carcinoma and cervical cancer. J. Clin. Oncol. 43, e17502. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e17502 (2025).","journal-title":"J. Clin. Oncol."},{"key":"77467_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-03985-4","volume":"23","author":"Y Jiang","year":"2025","unstructured":"Jiang, Y. et al. Efficacy and safety of cadonilimab (PD-1\/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial. BMC Med. 23, 152. https:\/\/doi.org\/10.1186\/s12916-025-03985-4 (2025).","journal-title":"BMC Med."},{"key":"77467_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ygyno.2021.04.034","volume":"162","author":"JA How","year":"2021","unstructured":"How, J. A. et al. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol. Oncol. 162, 24\u201331, https:\/\/doi.org\/10.1016\/j.ygyno.2021.04.034 (2021).","journal-title":"Gynecol. Oncol."},{"key":"77467_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.23.02132","volume":"42","author":"SN Westin","year":"2024","unstructured":"Westin, S. N. et al. Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J. Clin. Oncol. 42, 283\u2013299, https:\/\/doi.org\/10.1200\/JCO.23.02132 (2024).","journal-title":"J. Clin. Oncol."},{"key":"77467_CR16","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1200\/JCO.2025.43.16_suppl.5512","volume":"43","author":"SN Westin","year":"2025","unstructured":"Westin, S. N. et al. Durvalumab plus carboplatin\/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: longitudinal changes in circulating tumor DNA. J. Clin. Oncol. 43, 5512, https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5512 (2025).","journal-title":"J. Clin. Oncol."},{"key":"77467_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41586-025-09203-8","volume":"644","author":"Y Dai","year":"2025","unstructured":"Dai, Y. et al. PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature 644, 537\u2013546, https:\/\/doi.org\/10.1038\/s41586-025-09203-8 (2025).","journal-title":"Nature"},{"key":"77467_CR18","unstructured":"WHO Classification of Tumours Editorial Board. Female Genital Tumours. 5th edn, Vol. 4 (International Agency for Research on Cancer, 2020)."},{"key":"77467_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01274-7","volume":"19","author":"Y Jin","year":"2020","unstructured":"Jin, Y. et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol. Cancer 19, 154. https:\/\/doi.org\/10.1186\/s12943-020-01274-7 (2020).","journal-title":"Mol. Cancer"},{"key":"77467_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101833","volume":"5","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm phase 2 trial (TORAL). Cell Rep. Med. 5, 101833. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101833 (2024).","journal-title":"Cell Rep. Med."},{"key":"77467_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00509","volume":"7","author":"E Sanz-Garcia","year":"2023","unstructured":"Sanz-Garcia, E. et al. Tumor-na\u00efve circulating tumor DNA as an early response biomarker for patients treated with immunotherapy in early phase clinical trials. JCO Precis. Oncol. 7, e2200509. https:\/\/doi.org\/10.1200\/PO.22.00509 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"77467_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","volume":"35","author":"MA Gouda","year":"2023","unstructured":"Gouda, M. A. et al. Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST). Ann. Oncol. 35, 267\u2013275, https:\/\/doi.org\/10.1016\/j.annonc.2023.12.007 (2023).","journal-title":"Ann. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77467-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:24:37Z","timestamp":1791325477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77467-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77467"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77467-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.Z. is an employee of Nanjing Geneseeq Technology Inc., which performed the ctDNA sequencing and related bioinformatic analyses for this study. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10537"}}